This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brady, A. Search for Related Content Social Bookmarking                         What's this?

Lust for LIFE: losartan and type 2 diabetes

Cardiovascular morbidity and mortality in patients with diabetes in the LIFE study

Department of Medical Cardiology, Queen Elizabeth Building, Glasgow Royal Infirmary, G31 2ER, UK, a.j.brady{at}clinmed.gla.ac.uk

Key Words: Losartan • atenolol • hypertension • ARBs.

References

• Dahlof B., Devereux R., Kjeldsen SE et al. Cardiovascular mortality and morbidity in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Lindholm LH, Ibsen H., Dahlöf B. et al. Cardiovascular mortality and morbidity in patients with diabetes in the LIFE study. Lancet 2002;359:1004-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.[Abstract/Free Full Text]
• Brady AJ, Oliver MA, Pittard JB Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care. BMJ 2001;322:1463.[Free Full Text]
• Lewis EJ, Hunsicker LG, Bain RP et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. New Engl J Med 1993;329: 1456-62.[Abstract/Free Full Text]
• Bilous RW Angiotensin II receptor blockade and type 2 diabetic nephropathy. Br J Diabetes Vasc Dis 2002;2:101-05.[Abstract/Free Full Text]
• SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-64.[Abstract/Free Full Text]
• Staessen JA, Fagarda R., Thijsa L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson L., Zanchetti A., Carruthers S. et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment study. Lancet 1998; 351:1755-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansson L. The SCOPE trial. Oral Presentation, Hypertension Prague 2002, June 23rd-27th 2002. 19th Scientific Meeting of the International Society of Hypertension joint meeting with 12th European Meeting on Hypertension (European Society of Hypertension).

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 1, 45-46 (2003)
DOI: 10.1177/14746514030030010601


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brady, A. Search for Related Content Social Bookmarking                         What's this?